Immunotherapy boost may help prevent head and neck cancer return
NCT ID NCT03480672
First seen Feb 19, 2026 · Last updated May 16, 2026 · Updated 13 times
Summary
This study tested whether adding the immunotherapy drug pembrolizumab to standard chemoradiation after surgery helps prevent cancer from coming back in people with advanced head and neck cancer. About 211 participants who had their tumor completely removed were randomly assigned to receive either standard treatment or standard treatment plus pembrolizumab. The main goal was to see if the combination improves the time people live without their cancer returning or worsening.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HNSCC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Charité - Universitätsmedizin Berlin; Klinik für Radioonkologie und Strahlentherapie CVK
Berlin, Germany
-
Charité - Universitätsmedizin, CVK und CCM, Klinik für Hals-Nasen-Ohrenheilkunde
Berlin, Germany
-
Department of Head Medicine and Oral Health, University of Leipzig
Leipzig, 04103, Germany
-
Ernst von Bergmann Klinikum Potsdam, Zentrum für Hämatologie, Onkologie und Strahlenheilkunde, Klinik für Hämatologie und
Potsdam, Germany
-
Helios Klinikum Erfurt GmbH, Klinik für Hals-Nasen-Ohrenheilkunde
Erfurt, Germany
-
Kath. Marienkrankenhaus gGmbH, Zentrum für Innere Medizin Hämatologie/Onkologie
Hamburg, Germany
-
Klinikum Bielefeld, Onkologie/Hämatologie/ Palliativmedizin
Bielefeld, Germany
-
Klinikum Stuttgart - Katharinenhospital, Klinik für Radioonkologie und Strahlentherapie
Stuttgart, Germany
-
UNIVERSITÄTSKLINIKUM Schleswig-Holstein, Campus Lübeck
Lübeck, Germany
-
Universitätsklinikum Bonn; Med. Klinik III / ZIM, Hämatologie/Onkologie
Bonn, Germany
-
Universitätsklinikum Düsseldorf, Klinik für Strahlentherapie und Radiologische Onkologie
Düsseldorf, Germany
-
Universitätsklinikum Essen, Klinik und Poliklinik für Strahlentherapie
Essen, Germany
-
Universitätsklinikum Jena, Klinik für Hals-Nasen-Ohrenheilkunde
Jena, Germany
-
Universitätsklinikum Mannheim, Hals-Nasen-Ohren Klinik
Mannheim, Germany
-
Universitätsklinikum Regensburg, Klinik und Poliklinik für Strahlentherapie
Regensburg, Germany
-
Universitätsklinikum Würzburg; Klinik und Poliklinik für Strahlentherapie
Würzburg, Germany
Conditions
Explore the condition pages connected to this study.